Latest Breaking News On - Johnr adler - Page 9 : comparemela.com
Innovating to restore abilities lost to neurological damage
stanford.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stanford.edu Daily Mail and Mail on Sunday newspapers.
ZAP Surgical to Bring the Latest Non-Invasive Brain Tumor Treatment to Viamed Virgen de la Paloma Hospital in Madrid
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
(1)
Renowned Neuroscience Institute in Zurich To Soon Offer Next-Gen Non-Invasive Brain Cancer Treatment
ZAP Surgical Systems, Inc. today announced the imminent installation of its advanced ZAP-X Gyroscopic Radiosurgery platform at the Swiss Neuro Radiosurgery Center (SNRC), an organization within the Swiss Clinical Neuroscience Institute (SCNSI) in Zurich, Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005002/en/
ZAP-X Gyroscopic Radiosurgery Platform (Photo: Business Wire)
Stereotactic radiosurgery (SRS) is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors, as well as select intracranial functional and vascular disorders. Considered an alternative to surgery for these indications, SRS is a non-invasive outpatient procedure that often provides equivalent to superior outcomes, yet no surgical incision, and little to no recovery period.
Markets
In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Accuray (ARAY – Research Report), with a price target of $9.00. The company’s shares closed last Tuesday at $5.32, close to its 52-week high of $6.02.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 74.2% and a 64.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
Accuray has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
The company has a one-year high of $6.02 and a one-year low of $1.75. Currently, Accuray has an average volume of 790.2K.
ZAP Surgical Systems, Inc : ZAP Surgical Announces Future Installation of Novel Non-Invasive Brain Tumor Treatment System in Munich, Germany
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.